There is a well-recognized intersection between drugs of abuse and AIDS or other states of compromised immune function, but the mechanisms behind this interaction are just beginning to be revealed. Cross-talk between opioids or cannabinoids and chemokines (small proteins produced by both microglia and neurons in the brain) occurs both in vitro and in vivo. For example, heterologous cross-desensitization, in terms of reduced chemotactic and antinociceptive activities, occurs between opioids and chemokines that are involved in HIV entry into cells. Our findings since the last competing renewal demonstrate unequivocally that the opioid, cannabinoid, and chemokine systems interact in both the immune system and the nervous system. Our results, with those from other laboratories, have led us to propose that the chemokine system in the brain is a major communication system between neurons, and between glia and neurons, thus joining neuropeptides and neurotransmitters subserving this function in normal and pathological states. It is the purpose of the proposed studies to document the nature of the interactions among these three classes of ligands and their receptors. Specifically, we propose to 1) explore the functional and biological consequences of injection of selected chemokines into various brain areas in terms of their altering the actions of drugs of abuse, including analgesia, thermoregulation, tolerance,and dependence;2) examine the reciprocal effect of opioids and cannabinoids on the activity of chemokines in the brain, and 3) assess neurophysiological effects of the chemokines alone and with opioids or cannabinoids in brain slices. The drugs chosen alter levels of HIV when added to human lymphoid, monocytic, or microglial cultures in vitro and interact with the chemokine receptors involved in HIV infection. The chemokines to be studied are ligands for HIV chemokine co-receptors. The implications for public health include altering treatment of pain associated with neuroinflammatory states, treatment of neuropathies associated with HIV, altering the ability of HIV to enter cells, altering actions of neurotransmitter/neuropeptide systems involved in the effects of drugs abused or used therapeutically, and potentially bringing new approaches to prevention and treatment of drug abuse and neurodegenerative diseases and AIDS through affecting the actions of chemokines and their receptors in the nervous system.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA006650-19S1
Application #
8486744
Study Section
Special Emphasis Panel (ZRG1-AARR-A (05))
Program Officer
Purohit, Vishnudutt
Project Start
1991-03-20
Project End
2013-01-31
Budget Start
2012-07-01
Budget End
2013-01-31
Support Year
19
Fiscal Year
2012
Total Cost
$54,154
Indirect Cost
$18,759
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Robinson, Rebecca H; Meissler, Joseph J; Fan, Xiaoxuan et al. (2015) A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10. J Neuroimmune Pharmacol 10:318-32
Bednar, Filip; Song, Changcheng; Bardi, Giuseppe et al. (2014) Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1. J Immunol 192:5305-13
Robinson, Rebecca Hartzell; Meissler, Joseph J; Breslow-Deckman, Jessica M et al. (2013) Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J Neuroimmune Pharmacol 8:1239-50
Rogers, Thomas J (2012) The molecular basis for neuroimmune receptor signaling. J Neuroimmune Pharmacol 7:722-4
Zhang, Lily; Belkowski, Judith Sliker; Briscoe, Tammi et al. (2012) Regulation of mu opioid receptor expression in developing T cells. J Neuroimmune Pharmacol 7:835-42
Kaminsky, David E; Rogers, Thomas J (2011) Nociceptin/orphanin FQ receptor-driven heterologous desensitization of the major HIV-1 co-receptor CXCR4. J Neuroimmune Pharmacol 6:546-50
Heinisch, Silke; Palma, Jonathan; Kirby, Lynn G (2011) Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain Behav Immun 25:360-72
Happel, Christine; Kutzler, Michele; Rogers, Thomas J (2011) Opioid-induced chemokine expression requires NF-κB activity: the role of PKCζ. J Leukoc Biol 89:301-9
Song, Changcheng; Rahim, Rahil T; Davey, Penelope C et al. (2011) Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5. J Biol Chem 286:20354-65
Chen, Xiaohong; Kirby, Lynn G; Palma, Jonathan et al. (2011) The effect of gp120 on morphine's antinociceptive and neurophysiological actions. Brain Behav Immun 25:1434-43

Showing the most recent 10 out of 95 publications